Medipharm Labs Appoints Former Purdue Pharma Exec As CEO

Medipharm Labs (TSX: LABS) continues to suffer from management turnover. The company today announced that its CEO, Bryan Howcroft, will be stepping down for personal reasons effective immediately. Howcroft was in the role for just six months.

Taking Howcroft’s place within the company is that of David Piddick, whom Medipharm lists as previously serving as a president and CEO of a “Canadian pharmaceutical company.” That pharma company is believed to be Purdue Pharma Canada, whom notably faced numerous lawsuits related to the opioid pandemic which ultimately lead to a bankruptcy filing in the US. Piddick will also serve on the firms board of directors.

Piddick reportedly has over two decades worth of senior leadership experience within the healthcare industry. He currently holds a MBA from Northwestern University.

“In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team’s current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders,” commented Piddick on his appointment.

As part of Piddick’s compensation package, he was issued 14.8 million RSU’s in connection with his appointment, as well as 5.2 million stock options.

Howcroft meanwhile has exited his role from the firm entirely, announcing this morning he will also be vacating his position on the firms board.

Medipharm Labs last traded at $0.145 on the TSX.


Information for this briefing was found via Sedar and MediPharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

2 Responses

Video Articles

Why $100 Silver Right Now Would Be a Problem | Keith Neumeyer – First Majestic

Why Industrial Demand Is Changing the Silver Market | David Morgan

Gold and Silver Delivery Is Exposing the Paper Market | Andy Schectman

Recommended

Why $100 Silver Right Now Would Be a Problem | Keith Neumeyer – First Majestic

The Court Ruling And What Emerita Still Has In Play | David Gower – Emerita Resources

Related News

Champignon Brands Appoints Medipharm Labs CEO Pat McCutcheon to Board

This morning Champignon Brands Inc. (CSE: SHRM) announced the appointment of Pat McCutcheon to its...

Wednesday, May 6, 2020, 09:18:25 AM

PI Financial Discontinues Coverage On Medipharm Labs, Heritage Cannabis

Friday evening following the close of markets, a note was sent out by PI Financials...

Monday, September 28, 2020, 07:42:00 AM

Medipharm Labs Appoints New Chief Financial Officer

Medipharm Labs (TSX: LABS) announced this morning that they have replaced their chief financial officer....

Monday, November 4, 2019, 09:44:34 AM

Medipharm Labs Launches Self-Branded Line Of Products

Medipharm Labs (TSX: LABS) is launching its first branded products to the Canadian marketplace. This...

Thursday, March 26, 2020, 08:33:37 AM

Medipharm Labs Ships First Topical Products

Medipharm Labs (TSX: LABS) is now in the cannabis topicals business. The company announced this...

Wednesday, March 25, 2020, 08:20:53 AM